World diabetes day 2018: Battling the Emerging Epidemic of Diabetic Retinopathy

Pandey, Suresh K; Sharma, Vidushi

doi:10.4103/ijo.ijo_1681_18

Cited by 83 publications

(56 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In South Asia, India is deemed as the world's capital of diabetes. The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025 and 80 million by 2030, an increase of 266% [23]. The World Health Organization (WHO) has projected that T2DM is expected to be the seventh primary cause of death by 2030, when low-and middle-income countries will account for more than 80% of all deaths related to diabetes [24].…”

Section: Introductionmentioning

confidence: 99%

Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population

Noreen

Loffredo

Bhatti

et al. 2020

IJERPH

View full text Add to dashboard Cite

The epidemic of type 2 diabetes mellitus (T2DM) is an important global health concern. Our earlier epidemiological investigation in Pakistan prompted us to conduct a molecular investigation to decipher the differential genetic pathways of this health condition in relation to non-diabetic controls. Our microarray studies of global gene expression were conducted on the Affymetrix platform using Human Genome U133 Plus 2.0 Array along with Ingenuity Pathway Analysis (IPA) to associate the affected genes with their canonical pathways. High-throughput qRT-PCR TaqMan Low Density Array (TLDA) was performed to validate the selected differentially expressed genes of our interest, viz., ARNT, LEPR, MYC, RRAD, CYP2D6, TP53, APOC1, APOC2, CYP1B1, SLC2A13, and SLC33A1 using a small population validation sample (n = 15 cases and their corresponding matched controls). Overall, our small pilot study revealed a discrete gene expression profile in cases compared to controls. The disease pathways included: Insulin Receptor Signaling, Type II Diabetes Mellitus Signaling, Apoptosis Signaling, Aryl Hydrocarbon Receptor Signaling, p53 Signaling, Mitochondrial Dysfunction, Chronic Myeloid Leukemia Signaling, Parkinson’s Signaling, Molecular Mechanism of Cancer, and Cell Cycle G1/S Checkpoint Regulation, GABA Receptor Signaling, Neuroinflammation Signaling Pathway, Dopamine Receptor Signaling, Sirtuin Signaling Pathway, Oxidative Phosphorylation, LXR/RXR Activation, and Mitochondrial Dysfunction, strongly consistent with the evidence from epidemiological studies. These gene fingerprints could lead to the development of biomarkers for the identification of subgroups at high risk for future disease well ahead of time, before the actual disease becomes visible.

show abstract

Section: Introductionmentioning

confidence: 99%

Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population

Noreen

Loffredo

Bhatti

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…India's T2DM prevalence has been expected to increase upto 266% by 2030, with the urban population considered at a higher risk than the rural population [17]. This highlights an urgent need to highlight the importance of the need to undertake lifestyle modification among young adults.…”

Section: Introductionmentioning

confidence: 99%

Distribution of glycated haemoglobin and its determinants in Indian young adults

Nagarathna

Kaur

Anand

et al. 2020

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…Type 2 diabetes mellitus (T2DM) is a global pandemic, and India is steadily emerging as the diabetes capital of world [1]. The number of patients with diabetes in India is likely to reach 134.2 million by 2045 [2].…”

Section: Introductionmentioning

confidence: 99%

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)

Ghosh

Tiwaskar

Chawla³

et al. 2020

Diabetes Ther

View full text Add to dashboard Cite

Introduction: Teneligliptin is an antidiabetic medication that has been approved for the management of type 2 diabetes mellitus (T2DM) in Japan, South Korea and India. It is one of the most commonly prescribed antihyperglycaemic agents. The aim of this study was to assess the effectiveness of teneligliptin in improving glycemic control amongst Indian patients with T2DM in a real-world setting. Methods: This was a retrospective observational study in which a predesigned structured proforma was used to collect information from hospital records of 18 medical centres across India. All participating centres were established primary care hospitals with adequate record keeping, a predetermined condition in the study design. Data were collected during the period of January 2019 to June 2019. Data extracted from patient records, including glycaemic parameters, concomitant drugs, drug dosage and duration, were collated. The effectiveness of teneligliptin was assessed by analyzing the mean change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) at 12 weeks after initiation of teneligliptin. Results: Data from 10,623 patients were available for analysis. The mean age of the enrolled patients was 51.86 ± 11.76 years. At 12 weeks after initiation of teneligliptin as monotherapy or add-on to other medications (combination therapy), the patients showed a signficant decrease from baseline in mean HbA1c, FPG and PPG. Mean HbA1c dropped from 8.66 ± 1.

show abstract

World diabetes day 2018: Battling the Emerging Epidemic of Diabetic Retinopathy

Cited by 83 publications

References 6 publications

Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population

Transcriptional Profiling and Biological Pathway(s) Analysis of Type 2 Diabetes Mellitus in a Pakistani Population

Distribution of glycated haemoglobin and its determinants in Indian young adults

Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)

Contact Info

Product

Resources

About